MBrace focuses on developing ADC therapeutics, with lead candidate MBRC-101 that targets the EphA5 receptor tyrosine kinase expressed across multiple cancers. The company advances a proprietary SPARTA approach to accelerate antibody-based drug development for personalized medicine and has in-licensed novel candidates from Rutgers. MBrace plans to use the new funding to support clinical development programs, including a first-in-human Phase 1 study of MBRC-101 planned before year-end. The company has generated extensive preclinical data and will present MBRC-101 data at the San Antonio Breast Cancer Symposium. MBrace was founded in June 2020 and is headquartered in San Diego with research facilities at the Thomas O. Daniel Research Incubator and Collaboration Center at Bristol Myers Squibb in Summit, NJ. Financially, the company has now raised a total of $110 million to advance its oncology pipeline.

Total raised

$85M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2023